Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: Differential efficacy in diabetes?: Subgroup analysis from S-Access

Stroke

Volumn 40, Issue 8, 2009, Pages 2862-2865

  Shinohara, Yukito ^a   Nishimaru, Katsuya ^b  

^a Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Antiplatelets; Cerebrovascular diseases stroke; Clinical studies; Diabetes mellitus; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; SARPOGRELATE;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION; TREATMENT OUTCOME;

AGED; ASPIRIN; CEREBRAL INFARCTION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SECONDARY PREVENTION; SUCCINATES; TREATMENT OUTCOME;

EID: 68749112764     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.554246     Document Type: Article

References (7)

1. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367:606-617.
2. Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K, Tohgi H, Fukuuchi Y, Uchiyama S, Yamaguchi T, Kobayashi S, Kondo K, Otomo E, Gotoh F. S-ACCESS Study Group. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, doubleblind, aspirin-controlled trial. Stroke. 2008;39:1827-1833.
3. Miyazaki M, Higashi Y, Goto C, Chayama K, Yoshizumi M, Sanada H, Orihashi K, Sueda T. Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol. 2007;49:221-227.
4. Am Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31 Suppl 1:S12-S54.
5. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-2141.
6. Piechowski-Jozwiak B, Maulaz A, Bogousslavsky J. Secondary prevention of stroke with antiplatelet agents in patients with diabetes mellitus. Cerebrovasc Dis. 2005;20 Suppl 1:15-23.
7. Ováry C, Suzuki K, Nagy Z. Regional differences in incidence rates, outcome predictors and survival of stroke. Neuroepidemiology. 2004;23: 240-246.